An observational study in Solid Tumor, Hematologic Malignancy and Thoracic Cancer, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-03.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Hematologic Neoplasms by Assistance Publique - Hôpitaux de Paris — 6 open to participants now, 6 under way, 1 of them phase 3. Hematologic Neoplasms · Assistance Publique - Hôpitaux de Paris.
Among the 16 studies in Hematologic Neoplasms by Assistance Publique - Hôpitaux de Paris, this one is the only one that started in 2021, is one of 7 observational ones, and was the 12th registered.
1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.
Browse Hematologic Neoplasms studies →6 of the 16 studies in Hematologic Neoplasms by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–66
Assistance Publique - Hôpitaux de Paris · Sites in France
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 70+
Assistance Publique - Hôpitaux de Paris
Ages 18+
By country, each count listing its studies:
Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 191 across 324 observational studies indexed under Hematologic Neoplasms.
Median enrollment 51 across the 9 interventional studies, 500 across the 7 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
3 of the studies in Hematologic Neoplasms by Assistance Publique - Hôpitaux de Paris that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06350994Assistance Publique - Hôpitaux de ParisEarly Assessment of Cardiac Function After Treatment With CAR-T Cells | 2026-12 |
| NCT04707300Assistance Publique - Hôpitaux de ParisStudy Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO) | 2027-06 |
| NCT02884375Assistance Publique - Hôpitaux de ParisElderly CAncer Patient | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies in Hematologic Neoplasms by Assistance Publique - Hôpitaux de Paris, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In the context of malignant disease, it is likely that vaccine efficacy and immunogenicity depends on the type of pathology, stage of the disease, immunosuppression induced by the treatments, in addition to more classic factors such as age, general condition and possibly the type of vaccine used.
There are very little data on the efficacy and immunogenicity of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in patients with malignant disease in the active phase of treatment.
This multicenter observational study aims to assess the efficacy and the immunogenicity of anti-Sars-CoV-2 vaccines in the cohort of patients treated for malignant pathology (solid or hematological tumors) at Saint Louis Hospital and in thoracic oncology patients at Bichat Hospital.
During the visit carried out as part of the follow-up, participation in this study will be proposed to any patient who is treated for a malignant disease (solid or hematological tumors) within the university hospitals of AP-HP.Nord.
The patients participating in this prospective cohort will benefit from all standard care his/her condition requires.
Clinical and biological data will be collected as part of the usual follow-up. Clinical data: pathology, stage, treatment line, type of current treatment and date of the last treatment administered, previous treatments, radiotherapy, concept of radiation lung disease, history of pneumonectomy, comorbidities, performance status, history of coronavirus disease 2019 (COVID-19).
Laboratory data: pre-vaccination polynuclear neutrophil count, lymphocyte counts, plasma protein electrophoresis or Ig weight dosage (routine care in hematology), lactate dehydrogenase (LDH), C-reactive protein (CRP), albuminemia in the previous month.
Vaccination data: type of vaccine, date of the 1st injection, date of the 2nd injection, pre-vaccination antibody levels
During visits between D21 and D28 (before the 2nd injection), at month 3, month 6 and month 12, the following data will be collected:
Patients who are treated for a malignant disease (solid or hematological tumors) within the CHU AP-HP.Nord and who are willing to get a SARS-CoV-2 vaccination.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with malignant disease undergoing chemotherapy within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.
Other: Data collection
Patients with malignant disease undergoing chemotherapy + immunotherapy within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.
Other: Data collection
Patients with malignant disease undergoing immunotherapy within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.
Other: Data collection
Patients with malignant disease treated with targeted therapies within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.
Other: Data collection
Patients with malignant disease undergoing radiotherapy within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.
Other: Data collection
Assessment of the efficacy and immunogenicity of the anti-Sars-COv2 vaccines in patients treated for malignant pathology.
SARS-CoV-2 vaccine response at 12 months
IgG anti-Sarc-CoV-2 S-protein titer at 12 months
Time frame: 12 months
Seroprevalence of antibodies against Sarc-CoV-2 S-protein before vaccination
Rate of patients presenting the anti Sarc-CoV-2 S-protein antibodies before vaccination in the study population.
Time frame: Day 0
Seroprevalence of antibodies against Sarc-CoV-2 N-protein before vaccination
Rate of patients presenting the anti Sarc-CoV-2 N-protein antibodies before vaccination in the study population.
Time frame: Day 0
SARS-CoV-2 vaccine response after first dose of vaccine
IgG anti-Sarc-CoV-2 S-protein titer after the first injection of vaccine
Time frame: Day 24 +/- 4 days
SARS-CoV-2 vaccine response at 3 months
IgG anti-Sarc-CoV-2 S-protein titer at 3 months
Time frame: 3 months
SARS-CoV-2 vaccine response at 6 months
IgG anti-Sarc-CoV-2 S-protein titer at 6 months
Time frame: 6 months
SARS-CoV-2 vaccine safety in the study population
Occurence of the adverse events related to the SARS-CoV-2 vaccine
Time frame: 12 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jan 2021 (actual). Primary completion is estimated for Feb 2024, 37 months after the start.
Of 164 non-industry observational studies under Hematologic Neoplasms, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 322. This study's planned 37 months is below that.
Counting every sponsor, half of 186 studies reached it within 74 months; a quarter within 34 and three quarters within 322.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →